The U.S. 'may have missed a window' to produce 'an important bridge' to a coronavirus vaccine

Scott Gottlieb.
(Image credit: Mark Wilson/Getty Images)

Since the early days of the coronavirus pandemic, the United States has emphasized ratcheting up vaccine production even before federal approval so that, if and when the time comes, the stockpile is ready to go. The same can't be said about a potential treatment known as monoclonal antibodies, however, Stat News reports.

Monoclonal antibodies are pretty much what they sound like — antibodies that have been genetically engineered into new medicines. Immunologists and virologists are reportedly optimistic they could play a role in fighting COVID-19, and data from two separate clinical trials run by Regeneron Pharmaceuticals and Eli Lilly are expected to be released in the fall, possibly indicating whether the therapies are safe and effective.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.